204 hasil untuk "Mellinghoff, Ingo"
Menampilkan 1–20 · 0,31 detik · RSS
-
Artikel Jurnal Teks lengkap
Why Do Cancer Cells Become “Addicted” to Oncogenic Epidermal Growth Factor Receptor?
The author discusses three new studies inPLoS Medicine that shed light on the mechanisms involved in apoptosis triggered by EGFR kinase inhibitors.
-
Artikel Jurnal Teks lengkap
Dissecting Glioma Invasiveness in a 3D-Organotypic Model
Diffuse brain infiltration by tumor cells is a hallmark of glioma. Molecular mechanisms of brain invasion are poorly understood due to the difficulty to model this process in culture. A new study published in Cell Reports developed a three-dimensional organotypic model and identified interferon…
-
Artikel Jurnal Teks lengkap
MPTH-16 GENOMIC AND CLINICAL CHARACTERISTICS OF NF1-MUTATED GLIOBLASTOMA (GBM)
-
Artikel Jurnal Teks lengkap
Meningeal lymphatics prime tumor immunity in glioblastoma
The notion of the brain as an immune-privileged organ has been challenged by the discovery of functional lymphatic vessels in the meninges of the dorsal and basal skull. A study published in Nature last year shows that meningeal lymphatics play an important role in the sensing of brain tumor…
-
Artikel Jurnal Teks lengkap
Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy
Pediatric high-grade glioma (pHGG) is the leading cause of cancer death in children. Despite histologic similarities, it has recently become apparent that this disease is molecularly distinct from its adult counterpart. Specific hallmark oncogenic histone mutations within pediatric malignant…
-
Artikel Jurnal Teks lengkap
Glioblastoma and other Primary Brain Malignancies in Adults. A Review
IMPORTANCE: Malignant primary brain tumors cause over 15,000 deaths per year in the United States. The annual incidence of primary malignant brain tumors is approximately 7 per 100,000 individuals and increases with age. Five-year survival is about 67%. OBSERVATIONS: Malignant brain tumors include…
-
Artikel Jurnal Teks lengkap
Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma
The process of developing cancer therapies is well established and has enabled the incorporation of many new drugs and classes of agents into the standard of care for common cancers. Clinical drug development is fundamentally different for rare and difficult-to-treat solid tumors, such as glioma or…
-
Artikel Jurnal Teks lengkap
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) and concomitantly produce reduced nicotinamide adenine dinucleotide phosphate (NADPH) from NADP(+). Mutations in the genes encoding IDH1 and IDH2 have recently been found in a variety of human…
-
Artikel Jurnal Teks lengkap
Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
Epidermal growth factor receptor (EGFR) has emerged as a highly attractive therapeutic target in glioblastoma (GBM) based on its high frequency of gene amplification and mutation and its identification as an upstream trigger of dysregulated cell signaling cascades that drive GBM pathophysiology…
-
Artikel Jurnal Teks lengkap
Will Kinase Inhibitors Make it as Glioblastoma Drugs?
Kinase inhibitors have emerged as effective cancer therapeutics in a variety of human cancers. Glioblastoma (GBM), the most common malignant brain tumor in adults, represents a compelling disease for kinase inhibitor therapy because the majority of these tumors harbor genetic alterations that…
-
Artikel Jurnal Teks lengkap
Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma
Since the first discovery of isocitrate dehydrogenase (IDH) mutations in cancer, considerable progress has been made in our understanding of their contribution to cancer development. For glioma, this has helped to identify two diagnostic groups of tumors (oligodendroglioma and astrocytoma IDHmt)…
-
Artikel Jurnal Teks lengkap
Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology
The shift in cancer therapy from broadly cytotoxic agents toward “personalized” treatments that target specific alterations in each patient's tumor requires diagnostic pathology approaches that are quantitative and biospecimen-friendly. Novel multiplexed antibody-based imaging technologies can…
-
Artikel Jurnal Teks lengkap
Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation
-
Artikel Jurnal Teks lengkap
IDH Mutant Grade II and III Glial Neoplasms
Mutations in isocitrate dehydrogenase (IDH) 1 or IDH2 occur in the majority of adult low-grade gliomas and, less commonly, in cholangiocarcinoma, chondrosarcoma, acute myeloid leukemia, and other human malignancies. Cancer-associated mutations alter the function of the enzyme, resulting in…
-
Artikel Jurnal Teks lengkap
A Mathematical Methodology for Determining the Temporal Order of Pathway Alterations Arising during Gliomagenesis
Human cancer is caused by the accumulation of genetic alterations in cells. Of special importance are changes that occur early during malignant transformation because they may result in oncogene addiction and thus represent promising targets for therapeutic intervention. We have previously…
-
Artikel Jurnal Teks lengkap
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor
Classic work by Huggins and Hodges demonstrated that human prostate cancer regresses dramatically during antihormonal therapy but recurs frequently with androgen independence. Perturbations in the androgen receptor (AR) and PTEN–AKT signaling axes are significantly correlated with the progression…
-
Artikel Jurnal Teks lengkap
CTNI-66. IDH-MUTANT GLIOMA PATIENTS TREATED WITH VORASIDENIB: ONGOING DATA FROM THE VORASIDENIB EXPANDED ACCESS PROGRAM
BACKGROUND: Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1/2 (mIDH1/2) demonstrating clinical efficacy and safety in patients with mIDH1/2 glioma in the phase 3 INDIGO study (NCT04164901). Servier launched an expanded access program (EAP…